Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Short term Debt: 2015-2020

Historic Short term Debt for Fortress Biotech (FBIO) over the last 3 years, with Jun 2020 value amounting to $413,000.

  • Fortress Biotech's Short term Debt was N/A to $413,000 in Q2 2020 from the same period last year, while for Jun 2020 it was $413,000, marking a year-over-year change of. This contributed to the annual value of $27,000 for FY2019, which is 97.28% down from last year.
  • Per Fortress Biotech's latest filing, its Short term Debt stood at $413,000 for Q2 2020, which was up 498.55% from $69,000 recorded in Q1 2020.
  • Over the past 5 years, Fortress Biotech's Short term Debt peaked at $991,000 during Q4 2018, and registered a low of $16,000 during Q1 2019.
  • Over the past 3 years, Fortress Biotech's median Short term Debt value was $98,500 (recorded in 2018), while the average stood at $233,250.
  • As far as peak fluctuations go, Fortress Biotech's Short term Debt crashed by 97.28% in 2019, and later surged by 331.25% in 2020.
  • Quarterly analysis of 5 years shows Fortress Biotech's Short term Debt stood at $481,000 in 2016, then plummeted by 35.76% to $309,000 in 2017, then spiked by 220.71% to $991,000 in 2018, then crashed by 97.28% to $27,000 in 2019, then surged by 331.25% to $413,000 in 2020.
  • Its Short term Debt stands at $413,000 for Q2 2020, versus $69,000 for Q1 2020 and $27,000 for Q4 2019.